Bio-Rad laboratories (NYSE:BIO) stock has experienced a turbulent period with shareholders enduring a
54% loss over the past three years. Despite gapping up and down in the market, this biotech company is still considered by some as a classic Ariel stock. Lately, market share prices declined further, accumulating significant losses totaling 53%. Financial entities, such as
Sanctuary Advisors LLC and
Frank Rimerman Advisors LLC, have purchased shares of Bio-Rad. Furthermore, it's noted that
OncoCyte Corporation anticipates receiving a $10.2 million funding contribution from Bio-Rad. Updates include recent leadership changes with a new president, and COO being welcomed into the company. Also,
Bio-Rad revises their revenue forecast due to weak biotech demand, and an annual revenue forecast has been cut due to decreased diagnostics product demand. However, despite facing low biopharma demand and competitive pressure, Citi upgraded Bio-Rad shares to a 'buy' rating. It is also critical to note the company's recent $500M share repurchase program revealing positive performance forecast.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sat, 19 Oct 2024 18:18:53 GMT -
Rating -1
- Innovation 0
- Information 4
- Rumor -1
